News ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
17.02 ^USD	+0.53%		+9.81%	+14.30%

18/04	Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	MT
10/04	ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	30/04	GL
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	30/04	AQ
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting	24/04	GL
Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	19/04	MT
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	10/04	MT
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)	10/04	GL
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)	10/04	CI
UBS Adjusts ALX Oncology Price Target to $25 From $27, Maintains Buy Rating	13/03	MT
ALX Oncology : Corporate Presentation	12/03	PU
H.C. Wainwright Adjusts Price Target on ALX Oncology to $20 From $17.50, Keeps Buy Rating	11/03	MT
North American Morning Briefing : Stock Futures -2-	11/03	DJ
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $21 From $11, Maintains Overweight Rating	08/03	MT
Stifel Downgrades ALX Oncology Holdings to Hold From Buy, Adjusts Price Target to $14 From $10	08/03	MT
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/03	CI
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	08/03	GL
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	06/03	GL
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	06/03	AQ
Transcript : ALX Oncology Holdings Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 through Jan-11-2024	09/01
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Summary

Filters